Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Thursday 18 March, 2021

SkinBioTherapeutics

Holding(s) in Company

RNS Number : 7619S
SkinBioTherapeutics PLC
18 March 2021
 

SkinBioTherapeutics plc

 

Significant Shareholder

 

Manchester, UK - 18 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, provides an update on the shareholding of OptiBiotix Health Plc ("OptiBiotix") in the Company.

 

As part of the Placing and Open Offer announced 30 October 2020, the Company, OptiBiotix and Cenkos Securities plc ("Cenkos"), entered into a lock-in and orderly market agreement pursuant to which OptiBiotix agreed to certain undertakings. On 12 March 2021 OptiBiotix approached the Company and Cenkos seeking consent to sell two million shares in the Company. Noting the high demand for SBTX shares, the Company and Cenkos consented to the sale of the shares subject to maintaining an orderly market.

 

Consequent to the disposal of shares, OptiBiotix's holding in the Company has reduced to 36,138,569 shares representing 23.2% of the issued share capital.

 

All parties are committed to maintaining the terms of the lock-in agreement for the remainder of its term and there is no expectation that a further consent request will be made by or granted to OptiBiotix.

 

 

TR-1: S tandard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :

 

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligation iv

Name

Optibiotix Health PLC

City and country of registered office (if applicable)

York (UK)

4. Full name of shareholder(s) (if different from 3.) v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached vi :

17 March 2021

6. Date on which issuer notified (DD/MM/YYYY):

18 March 2021

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer vii

Resulting situation on the date on which threshold was crossed or reached

23.18

 

23.18

155,889,922

Position of previous notification (if

applicable)

24.46

 

24.46

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary

36,138,569

 

23.18

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

36,138,569

23.18

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlement xii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information xvi

Change due to sale of shares

         

 

Place of completion

Edinburgh

Date of completion

18 March 2021

 

 

 

 

-Ends-

 For more information, please contact:

SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

 

 

Cenkos Securities Plc (Nominated Adviser & Broker)
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)

Tel: +44 (0) 20 7397 8900

 

 

Instinctif Partners
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis

Tel: +44 (0) 20 7457 2020
[email protected]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLJPMITMTMBBBB

a d v e r t i s e m e n t